Adcirca 20mg Container 60 024 03
Adcirca Tablet
Product Images NDC 66302-467
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Adcirca (NDC 66302-467). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by United Therapeutics Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Structural Formula (Adcirca Chem V1)
Figure 1 (Adcirca Fig1 V1)
The text appears to be a table of data showing the maximum decrease in blood pressure (both systolic and diastolic) when Tadalafil 20mg and Tadalafil 10mg were coadministered with other drugs such as Alcohol, Alfuzosin, Amlodipine, Angiotensin Il Receptor Blocker, Doxazosin, Tamsulosin, Bendroflumethiazide, Enalapril, and Metoprolol, as well as a comparison to placebo. It does not provide any information about the purpose or context of the study.*
Figure 2 (Adcirca Fig2 V1)
This appears to be a drug interaction chart showing the effect of different drugs on Tadalafil, which is used to treat erectile dysfunction. The chart lists the fold change and 90% confidence interval (AUC and Cmax) of Tadalafil when administered with other drugs, including CYP3A inhibitors and inducers, antacids, and H2 antagonists. It also provides recommendations for dose adjustments and whether to avoid use of certain drugs with Tadalafil.*
Figure 3 (Adcirca Fig3 V1)
This text appears to be describing the effects of coadministered drugs on other drugs metabolized by various enzymes or substrates. The text provides information on the fold change in AUC and Cmax values and the recommendation of dose adjustment. The drugs and substrates mentioned include Theophylline, Warfarin, Midazolam, Lovastatin, Bosentanb, Digoxin, Oral Contraceptives, and NSAIDs. The recommended dose adjustment for the coadministered drugs appears to be no dose adjustment.*
Figure 4 (Adcirca Fig4 V1)
The text represents a chart or graph showing the mean change in meters from a baseline measurement in a clinical trial. The Y-axis measures the amount of change, while the X-axis represents the number of weeks in the trial. The graph includes two groups, a placebo group (N=82) and a group taking ADCIRCA 40 mg (N=79). There are three asterisks indicating three significant differences between the groups at different time points. However, it is not clear what the specific intervention or condition being measured is without additional information.*
Figure 5 (Adcirca Fig5 V1)
This is a table showing the results of a study on the effects of ADCIRCA 40mg on various parameters such as the 6-minute walk distance in subjects with pulmonary arterial hypertension (PAH) of different etiologies. The subjects were divided based on gender, age, baseline 6-minute walk distance, and WHO functional class. Some subjects had repaired congenital pulmonary shunts. The placebo-adjusted mean change in the 6-minute walk distance is reported with confidence intervals. No further information is available.*
Figure 6 (Adcirca Fig6 V1)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
